Skip to main content
. 2012 Feb 8;7(2):e30286. doi: 10.1371/journal.pone.0030286

Figure 1. Effect of 17-AAG and CsA on HCV replication and viability determined by intracellular esterase activity.

Figure 1

Antiviral activity (measured using the Renilla luciferase encoded by the HCV replicon; gray) and cell viability (measuring through the cleavage of calcein-AM by intracellular esterases; black) were assessed as a function of dose in a three day assay for the following molecules: (A) the HCV polymerase inhibitor HCV-796, (B) the ribosomal inhibitor puromycin, (C) the cyclophilin inhibitor CsA, (D) the microtubule inhibitor colchicine, (E) the anti-metabolite gemcitabine, and (F) the HSP90 inhibitor 17-AAG.